Lazertinib

MADRID — The combination of amivantamab and lazertinib improved PFS compared with osimertinib as first-line treatment for EGFR-mutated advanced non-small cell lung cancer, according to study results presented at ESMO Congress.

Amivantamab plus lazertinib improved PFS compared with osimertinib as first-line therapy in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

Amivantamab-vmjw — with or without the addition of lazertinib — improved PFS versus chemotherapy alone in patients with EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.

Amivantamab-vmjw conferred long-term clinical response in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutations, according to data from the agent’s manufacturer.

In this video, Ravi Salgia, MD, PhD, highlighted two studies that investigated treatment for EGFR-mutated non-small cell lung cancer presented at ASCO Annual Meeting.

Amivantamab and lazertinib can be combined safely at their monotherapy doses for patients with advanced EGFR-mutated non-small cell lung cancer, according to results of the phase 1 CHRYSALIS study presented at ESMO Virtual Congress 2020.